Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now early-phase tilt small index

Diabetic Neuropathy: early-phase trial registry

1 of 9 indexed Diabetic Neuropathy trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #1,916 of 28,707 conditions by registered trial count.

9 US clinical trials · 1 currently recruiting · #1,916 of 28,707 conditions by registered trial count

Diabetic Neuropathy: 9 US clinical trials tracked, 1 recruiting.

Diabetic Neuropathy is the subject of 9 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most active sponsor is Avanir Pharmaceuticals, running 1 of these trials.

Enrollment posture brief

Registry condition diabetic-neuropathy

OPEN 1 | RECR 11% | LATE 2 | EARLY 4 | RANK #1916 | SPON 1

Nearest open-share peer: Alcohol Use Disorders (11% recruiting · 9 trials)

Acute Lymphoblastic Leukemia55.6%Acute Respiratory Distress S55.6%Acute Otitis Media22.2%Acute Heart Failure11.1%Diabetic Neuropathy (this)11%
Open-enrollment share among volume-matched conditions near Diabetic Neuropathy

Diabetic Neuropathy lists 1 open slots (11% of 9 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Diabetic Neuropathy on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Diabetic Neuropathy is recruiting below its size-band peers.

    1 of 9 indexed trials (11.1%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Diabetic Neuropathy trials is spread across many organizations.

    Avanir Pharmaceuticals accounts for 1 of 9 trials (11.1%). 9 distinct sponsors appear on at least one study for this condition label.

  3. Typical Diabetic Neuropathy enrolment sits around 128 participants.

    Median target enrolment is 128 among the 9 trials that report a genuine target (sentinel values excluded). 3 of those (33.3%) plan for fewer than 100 participants.

  4. Diabetic Neuropathy research is mostly interventional.

    8 interventional and 1 observational studies make up this index (88.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 24Phase 31Phase 41

Open and recent trials

9 total, page 1 of 1

RECRUITING NA 80 participants

Clinical Outcomes Related to Treatment of Distal Symmetric Polyneuropathy Using Semiconductor Embedded Therapeutic Socks

Endocrine Research Solutions

NCT06452914

ACTIVE NOT RECRUITING 300 participants

Long COVID-19 Cutaneous Signatures: An ARPA Funded Research Project

CND Life Sciences

NCT07005947

COMPLETED Phase 3 450 participants

Safety and Efficacy of Dextromethorphan and Quinidine in the Treatment of the Pain of Diabetic Neuropathy

Avanir Pharmaceuticals

NCT00113620

COMPLETED Phase 2 140 participants

Safety and Efficacy Study of QR-333 in Patient's With Symptomatic Diabetic Neuropathy

Quigley Pharma

NCT00568035

COMPLETED Phase 2 138 participants

The Efficacy and Safety of Clonidine Hydrochloride Topical Gel, vs Clonidine Hydrochloride Gel Comparator to Treat Painful Diabetic Neuropathy

BioDelivery Sciences International

NCT02643251

COMPLETED Phase 2 128 participants

Study of DA-9801 to Treat Diabetic Neuropathy

NeuroBo Pharmaceuticals

NCT01822925

COMPLETED NA 124 participants

Basket Study (CT-100-002) to Evaluate the Effects of a DiNaMo™ Component Training

Click Therapeutics

NCT05573685

COMPLETED Phase 4 62 participants

A Study Of Lidocaine Patch 5% Alone, Gabapentin Alone, And Lidocaine Patch 5% And Gabapentin In Combination For The Relief Of Pain In Patients With Diverse Peripheral Neuropathic Pain Conditions

Endo Pharmaceuticals

NCT00904202

COMPLETED Phase 2 52 participants

The Effect of Ruboxistaurin on Small Fiber Function

Chromaderm

NCT00190970

Phase Distribution

PhaseTrial count
Phase 2 4
Phase 3 1
Phase 4 1

Named interventions

Most-linked intervention names on Diabetic Neuropathy records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Neurodex Drug
1 trials
Gabapentin 300 mg capsules 1800 mg/day + placebo patch Drug
1 trials
Gabapentin + Lidoderm® Drug
1 trials
Gabapentin + Placebo Drug
1 trials
Placebo capsules + Lidoderm® Drug
1 trials
Placebo Capsules + Placebo Patch Drug
1 trials
Clonidine Hydrochloride Gel Comparator Drug
1 trials
Clonidine Hydrochloride Topical Gel, 0.1% Drug
1 trials

US sites by state

Facility locations filed on Diabetic Neuropathy trials. A trial with sites in several states counts in each.

Florida 5 trials
New York 4 trials
California 4 trials
Arizona 4 trials
Washington 2 trials
Texas 2 trials
South Carolina 2 trials
Missouri 2 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Diabetic Neuropathy page

9 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Diabetic Neuropathy condition card totals 9 registered trials; most-linked intervention Neurodex; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.